Spread the love
German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, the two companies said on Thursday.
For more coronavirus news, visit our dedicated page.
“Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries,” they said.
Financial terms were not disclosed.
Read more:
Germany says it needs third vaccine to make inoculation universal
Germany starts coronavirus vaccines a day early
Germany, Denmark mull delaying second COVID-19 vaccine shot